Abstract

Tuberculosis (TB) remains a leading cause of death from an infectious disease worldwide, partly due to a lack of effective strategies to screen and triage individuals with potential TB. Whole blood RNA signatures have been tested as biomarkers for TB, but have failed to meet the World Health Organization’s (WHO) optimal target product profiles (TPP). Here, we use RNA sequencing and machine-learning to investigate the utility of plasma cell-free RNA (cfRNA) as a host-response biomarker for TB in cohorts from Uganda, Vietnam and Philippines. We report a 6-gene cfRNA signature, which differentiates TB-positive and TB-negative individuals with AUC = 0.95, 0.92, and 0.95 in test, training and validation, respectively. This signature meets WHO TPPs (sensitivity: 97.1% [95% CI: 80.9-100%], specificity: 85.2% [95% CI: 72.4-100%]) regardless of geographic location, sample collection method and HIV status. Overall, our results identify plasma cfRNA as a promising host response biomarker to diagnose TB.

Whole blood signatures have served as the potential biomarkers for TB but failed to meet World Health Organization’s (WHO) optimal target product profiles (TPP). By employing cohorts from multiple countries, the authors identify a diagnostic 6-gene signature from cell free RNA which outperforms TPP requirement in distinguishing TB from non-TB.

Details

Title
Circulating cell-free RNA in blood as a host response biomarker for detection of tuberculosis
Author
Chang, Adrienne 1   VIAFID ORCID Logo  ; Loy, Conor J. 1 ; Eweis-LaBolle, Daniel 1   VIAFID ORCID Logo  ; Lenz, Joan S. 1 ; Steadman, Amy 2 ; Andgrama, Alfred 3 ; Nhung, Nguyen Viet 4 ; Yu, Charles 5 ; Worodria, William 6 ; Denkinger, Claudia M. 7   VIAFID ORCID Logo  ; Nahid, Payam 8 ; Cattamanchi, Adithya 9   VIAFID ORCID Logo  ; De Vlaminck, Iwijn 1   VIAFID ORCID Logo 

 Cornell University, Meinig School of Biomedical Engineering, Ithaca, USA (GRID:grid.5386.8) (ISNI:0000 0004 1936 877X) 
 Inc., Global Health Labs, Bellevue, USA (GRID:grid.450107.7) 
 World Alliance for Lung and Intensive Care Medicine in Uganda, Kampala, Uganda (GRID:grid.450107.7) 
 National Lung Hospital, Hanoi, Vietnam (GRID:grid.470059.f) 
 De La Salle Medical and Health Sciences Institute, Dasmarinas, Philippines (GRID:grid.470059.f) 
 World Alliance for Lung and Intensive Care Medicine in Uganda, Kampala, Uganda (GRID:grid.470059.f) 
 University Hospital Heidelberg & German Center of Infection Research, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908) 
 University of California San Francisco, UCSF Center for Tuberculosis, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 University of California San Francisco, UCSF Center for Tuberculosis, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California Irvine, Division of Pulmonary and Critical Care Medicine, Orange, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243) 
Pages
4949
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3066163424
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.